Current Report Filing (8-k)
November 16 2020 - 7:31AM
Edgar (US Regulatory)
0001061983
false
0001061983
2020-11-13
2020-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event Reported):
November 13, 2020
Cytokinetics, Incorporated
(Exact Name of Registrant as Specified in Charter)
Delaware
|
000-50633
|
94-3291317
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
280 East Grand Avenue, South San Francisco, California 94080
|
(Address of Principal Executive Offices) (Zip Code)
|
(650) 624-3000
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
CYTK
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.01. Completion of Acquisition or Disposition of Assets.
On November 13, 2020, Cytokinetics, Incorporated (“Cytokinetics”)
and RTW Royalty Holdings Designated Activity Company (f/k/a Dolya Holdco 19 Designated Activity Company) (“RTW Royalty Holdings”)
closed the previously announced sale of all of Cytokinetics’ rights to receive certain payments on the net sales of products
containing the compound mavacamten under that certain Research Collaboration Agreement, dated August 24, 2012, by and between Cytokinetics
and MyoKardia, Inc. pursuant to that certain Royalty Purchase Agreement, dated July 14, 2020, by and between Cytokinetics and RTW
Royalty Holdings (the “Royalty Purchase Agreement”). At the closing, Cytokinetics received a one-time payment of $85
million.
The foregoing description of the Royalty Purchase Agreement is not
complete and is qualified in its entirety by reference to the full text of the Royalty Purchase Agreement, a copy of which is filed
as Exhibit 10.3 to Cytokinetics’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November
6, 2020 and is incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CYTOKINETICS, INCORPORATED
|
|
|
|
Date: November 16, 2020
|
|
By:
|
/s/ Ching Jaw
|
|
|
|
Ching Jaw
|
|
|
|
Senior Vice President, Chief Financial Officer
|
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024